Traws Pharma (TRAW) Net Cash Flow (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Net Cash Flow of -$679000.0 for Q1 2026, up 87.48% year-over-year from -$362168.9 in Q1 2025, and up 73.88% quarter-over-quarter from -$2.6 million in Q4 2025.
Traws Pharma (TRAW) Net Cash Flow (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Net Cash Flow for 15 consecutive years, with -$679000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 87.48% year-over-year to -$679000.0; the TTM figure through Mar 2026 stood at -$10.2 million (up 5.35% YoY), while the FY2025 annual figure was -$17.6 million, down 3377.24% from the prior year.
- Net Cash Flow improved to -$679000.0 in Q1 2026 per TRAW's latest filing, from -$2.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $15.9 million in Q4 2024 and bottomed at -$11.5 million in Q3 2024.
- Historically, Net Cash Flow has averaged -$3.5 million across 5 years, with a median of -$4.3 million in 2022.
- On a YoY basis, Net Cash Flow climbed as much as 459.75% in 2024 and fell as far as 156.79% in 2024.
- Traws Pharma's Net Cash Flow stood at -$3.9 million in 2022, then fell by 14.06% to -$4.4 million in 2023, then surged by 459.75% to $15.9 million in 2024, then plunged by 116.31% to -$2.6 million in 2025, then soared by 73.88% to -$679000.0 in 2026.
- Business Quant data shows TRAW's Net Cash Flow at -$679000.0 in Q1 2026, -$2.6 million in Q4 2025, and -$4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.87 Bn | 78.87 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.40 Bn | 60.22 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.36 Bn | 54.22 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.91 Bn | 28.60 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.17 Bn | 9.78 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 225.59 Mn |
| 10 | Traws Pharma | 5.54 Mn | 519,253.28 | - | 1.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -679,000.00 |
| Mar 31, 2026 | -679,000.00 |
| Dec 31, 2025 | -2.60 Mn |
| Dec 31, 2025 | -2.60 Mn |
| Sep 30, 2025 | -4.07 Mn |
| Sep 30, 2025 | -4.07 Mn |
| Jun 30, 2025 | -2.88 Mn |
| Jun 30, 2025 | -2.88 Mn |
| Mar 31, 2025 | -5.42 Mn |
| Mar 31, 2025 | -5.42 Mn |
| Dec 31, 2024 | 15.94 Mn |
| Dec 31, 2024 | 15.94 Mn |
| Sep 30, 2024 | -11.48 Mn |
| Sep 30, 2024 | -11.48 Mn |
| Jun 30, 2024 | -9.85 Mn |
| Jun 30, 2024 | -9.85 Mn |
| Mar 31, 2024 | -4.42 Mn |
| Mar 31, 2024 | -4.42 Mn |
| Dec 31, 2023 | -4.43 Mn |
| Dec 31, 2023 | -4.43 Mn |